Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

A quality improvement strategy can improve electronic health record-based screening for depression and anxiety in people with epilepsy.

The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool's ...

Biohaven Ltd. will present an investor presentation detailing its ongoing and planned trials for various development programs, including troriluzole, taldefgrobep ...

Individuals living near golf courses, as well as those who reside in water service areas that include golf courses, are at ...

The Spinocerebellar Ataxia pipeline is advancing fast as troriluzole nears FDA nod and rivals race with gene and stem cell therapies to seize market edge. Disease modification in spinocerebellar ...

We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at ...

Biohaven has started a randomised Phase II/III trial of the TYK2 / JAK1 inhibitor, BHV-8000, aimed at treating early ...

In addition to TD Cowen, Biohaven Ltd. also received a Buy from William Blair’s Myles Minter in a report issued today. However, yesterday, RBC Capital maintained a Hold rating on Biohaven Ltd. (NYSE: ...

Timashev covers the Healthcare sector, focusing on stocks such as Biohaven Ltd., Legend Biotech, and Edgewise Therapeutics. Biohaven Ltd. has an analyst consensus of Strong Buy, with a price target ...

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...